HALIFAX, June 2 /CNW/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine
development company, launched the Warwick Kimmins Science Scholarship today to
high school students in Atlantic Canada. The scholarship is aimed at
encouraging students to pursue science in university.
"I want young people to be inspired by science," said Brian Lowe, Vice
President of IVT. "This gives students, who may not be at the top of their
class, a chance to win a scholarship and to dream big."
To apply for this scholarship, students must complete the application
form and submit an essay on what scientific breakthrough they would like to
make and why. The deadline to apply is June 13, 2008. Students may apply
online at www.immunovaccine.com.
The scholarship is in memory of IVT's founder, Dr. Warwick Kimmins.
Kimmins, who was also the former Dean of the Faculty of Science at Dalhousie
University, was instrumental in bringing IVT to where it is today.
ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine
development company. Through its own biotech research, patented VacciMax(R)
and DepoVax(TM) technologies, and collaborations with partners, IVT creates
vaccines with the potential to help save and improve lives around the world.
In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based
Immunotope Inc. The acquisition enables IVT to create an entire pipeline of
proprietary therapeutic cancer and infectious-disease specific vaccines. In
January 2008, IVT licensed its technology to Pfizer Animal health, marking a
pivotal step in achieving its vision of delivering breakthrough vaccines.
For further information:
For further information: Brian Lowe, Vice President IVT, (902) 492-1819,
email@example.com; Jennifer Ayotte, Communications, (902) 209-4704,